Amoy Diagnostics and Illumina are embarking on a collaboration to speed up the adoption of precision medicine and targeted therapies in China.
Amoy will develop and commercialize a series of oncology-related tests based on Illumina's next-generation sequencing (NGS) platforms, including the recently released research-use-only TruSight Tumor 15 as transferred from Illumina to Amoy. The collaboration mirrors the commitment made by both companies to offer integrated solutions to meet China’s clinical needs.
"Our genetic tests for detection of EGFR, KRAS, NRAS, and BRAF mutations, and ALK and ROS-1 fusions, have led the way for precision medicine adoption in clinical oncology across China. However, as the number of clinically actionable genetic variants in cancer increases, NGS technology is crucial in order for companion diagnostics to keep pace. Illumina is the world-leader in NGS and a natural partner for our company. We intend to combine Amoy's expertise in molecular diagnostics with Illumina's superior NGS technology to better serve Chinese cancer patients," said Dr. Limou Zheng, CEO and president of Amoy Diagnostics, in a statement.
Commenting on the strategic collaboration, Dr. Rick Klausner, senior vice president and chief medical officer of Illumina, said in a statement, “We are excited to announce this strategic collaboration with Amoy, which will increase access to our advanced NGS technology in the clinical oncology market in China. Genetic changes are a major cause of cancer development, and the number of clinically actionable genomic variants is growing rapidly. NGS technology, with its ability to generate and analyze large-scale data and its high sensitivity in detecting rare mutations, has shown great value and potential for oncology. Working with market leaders such as Amoy is central to Illumina's strategy to advance personalized cancer diagnostics globally."